護城河比較

Samsung leads three of its four principal markets — Q1 2026 DRAM revenue share 38.5% ($37.32B, TrendForce, https://www.trendforce.com/presscenter/news/20260601-13070.html), Q1 2026 NAND share 31.6% ($13.51B, TrendForce, https://www.trendforce.com/presscenter/news/20260525-13058.html), and #1 in Q2 2026 smartphones at 24% (Counterpoint via Android Authority, https://www.androidauthority.com/counterpoint-research-q2-2026-smartphone-shipment-report-3686931/) — but the moat is narrow, not wide: memory economics are violently cyclical (industry DRAM revenue swung +81% QoQ on contract-price spikes per the same TrendForce release), SK hynix holds the highest HBM bit-shipment mix among the top three (same release), and foundry trails TSMC 6.5% vs ~72% share (TrendForce data via TelecomLead, https://telecomlead.com/semiconductor/global-foundry-market-hits-record-47-95-bn-in-q1-2026-as-ai-chip-demand-drives-growth-tsmc-expands-share-to-72-126247).

來源：news.samsung.com

Corning's FY2025 Form 10-K (filed 12 February 2026) documents real protection in two places and hedges everywhere else. In Display it states flatly that 'We are the largest worldwide producer of glass substrates for flat panel displays' and credits a 'proprietary fusion manufacturing process, which we invented and is the cornerstone of our technology leadership in the display glass industry'; in Optical Communications it says 'We maintain a leadership position in the segment's principal product groups, which include carrier and enterprise networks'. But the Competition section opens on a company-wide concession - 'Some of these competitors are larger than we are, and some have broader product lines' - and closes that opening paragraph with 'There is no assurance that we will be able to maintain or improve our market position or competitive advantage', a hedge set over the five per-segment paragraphs that follow, the last of which has Life Sciences facing 'competition from large distributors that have pursued backward integration or introduced private label products'. In optical it expects 'industry consolidation, pricing pressure and competition for the innovation of new products' to persist. The risk factors add that Optical Communications and Display 'generate a significant amount of the Company's profits and cash flow' and are 'subject to pricing pressure', while the customer base is concentrated enough that customers 'may possess substantial leverage in negotiating contractual obligations' - the filing's own table puts two combined end customers at 28% of 2025 Optical Communications segment net sales, three at 59% of Display, two at 43% of Specialty Materials and three at 61% of Automotive. Protection that is genuine but confined to part of the portfolio, held against named larger rivals and customers with that much leverage, is narrow rather than wide.

來源：sec.gov

The FY2025 10-K supports a real but bounded advantage. The Competition section says the company believes "mRNA as a medicine coupled with our capabilities across mRNA technology, drug discovery, development and manufacturing provide us with a competitive advantage," and the Intellectual Property section backs that with more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed outside the U.S., 485 pending applications, and latest-to-expire granted patents on all three approved products projected to 2041 in the U.S. and 2036 in Europe. Item 1A cuts the band down from wide: it opens the competition risk with "The vaccine market, and pharmaceutical market more generally, is intensely competitive," says Moderna "ha[s] been excluded from selling our COVID vaccines in many European markets due to a competitor's contract with the European Commission, which does not lapse until year-end 2026," that in RSV it "entered a market already occupied by two larger competitors," and that rivals "have exploited and may in the future exploit their greater size, infrastructure, resources and experience." The same section reports net losses of $2.8 billion in 2025 and $3.6 billion in 2024 against 2025 total revenue of $1.9 billion.

來源：sec.gov

The durable advantage is manufacturing scale and capital intensity: the top three DRAM suppliers take roughly $8.97 of every $10 of industry revenue (Samsung 38.5% + SK hynix 28.8% + Micron 22.4% in Q1 2026 per TrendForce, https://www.trendforce.com/presscenter/news/20260601-13070.html), a structure sustained by multi-billion-dollar fab economics that has admitted no new large entrant in decades; Samsung is the largest-revenue producer in both DRAM and NAND (TrendForce, https://www.trendforce.com/presscenter/news/20260525-13058.html).

來源：news.samsung.com

What the filing keeps pointing at is invented process technology and the patent estate fencing it, not a network and not raw size. The FY2025 10-K repeats 'Patent protection is important to the segment's operations' word for word in four of its five reportable segments - Optical Communications, Specialty Materials, Automotive and Life Sciences - and gives Display a stronger variant, 'Patent protection and proprietary trade secrets are important to the Display segment's operations'. It reports about 11,375 unexpired patents owned worldwide at the end of 2025 (about 4,015 of them U.S.), about 370 U.S. and over 970 non-U.S. grants during 2025 and about 5,650 applications in process, and states 'We have historically enforced, and will continue to enforce, our intellectual property rights.' The single clearest asset is a process rather than a product - the fusion draw Corning says it invented and calls the cornerstone of its display-glass technology leadership, guarded in Display by 'proprietary trade secrets'. Even the cost advantage the filing claims in optical is sourced back to the same place: 'Our large-scale manufacturing experience, fiber process, technology leadership and intellectual property provide cost advantages relative to several of our competitors' - scale is described there as a consequence of the process, not the origin of the advantage, which is why this is an IP-and-know-how moat rather than a cost-scale one. The estate is broad rather than cliff-edged: 'no one patent is considered material to any segment', and about 740 worldwide patents, 6.5% of the portfolio, expire between 2026 and 2028.

來源：sec.gov

The filing locates the advantage in a patent and know-how estate, not in customer lock-in or cost. Intellectual Property describes "an expansive, multi-layered IP estate" whose platform claims cover mRNA chemistry, sequence optimization, engineering elements, LNP delivery systems and "innovative processes for the manufacture and analysis of mRNA drug substance and formulated drug product," alongside "substantial proprietary know-how associated with related manufacturing processes" and a trademark portfolio of at least 1,400 registrations. Nothing in the filing claims switching costs or a cost advantage; Item 1A says the opposite, that competitors leverage "larger supply chains and greater purchasing power."

來源：sec.gov

Revenue leader in DRAM (38.5%) and NAND (31.6%) in Q1 2026 (TrendForce) and #1 in Q2 2026 smartphone shipments (Counterpoint), but not the leader where AI value concentrates: SK hynix has the highest HBM bit-shipment mix among the top three DRAM suppliers (TrendForce, https://www.trendforce.com/presscenter/news/20260601-13070.html) and TSMC dominates foundry with ~72% share to Samsung's 6.5% (TrendForce via TelecomLead).

來源：news.samsung.com

The FY2025 10-K makes exactly one unqualified rank claim and it is Display: 'We are the largest worldwide producer of glass substrates for flat panel displays', with only AGC Inc. and Nippon Electric Glass Co., Ltd. named as principal competitors. The second-strongest claim is Optical Communications' - 'We maintain a leadership position in the segment's principal product groups, which include carrier and enterprise networks' - asserted against Amphenol, Fujikura and its subsidiary America Fujikura Ltd., Sumitomo and Prysmian Group S.p.A. Those two lines carry the company: Optical Communications was 38% of total segment net sales in 2025 and Display 23%, and the segment table credits them with $1,048 million and $993 million respectively of the $2,747 million of reportable-segment net income. The band is a company-level judgment weighted to them, and it does not extend across the portfolio - Automotive claims only 'a strong market position', and Life Sciences describes itself as 'a leading developer, manufacturer and global supplier of laboratory products for over 110 years' while competing against the much larger Thermo Fisher Scientific Inc. and Danaher Corporation on $972 million of 2025 sales.

來源：sec.gov

The Business section opens with the company's own claim that "Moderna is a pioneer and leader in the field of mRNA medicine." The Competition section frames the commercial reality more narrowly as a contest against a small named set: "We largely compete against Pfizer and BioNTech for sales of our COVID vaccines, whose vaccine is also based on mRNA technology. We also compete against other vaccines, including Sanofi and Novavax's." It does not claim a rank anywhere, and it places Moderna behind in the other approved category: in RSV "we compete against Pfizer and GlaxoSmithKline, who entered the U.S. market prior to us, and our RSV sales have been minimal to date."

來源：sec.gov

Current pricing is extraordinary but cyclical, not structural: conventional DRAM contract prices rose roughly 93-98% QoQ in Q1 2026 (TrendForce, https://www.trendforce.com/presscenter/news/20260601-13070.html) — shortage-driven commodity pricing that reverses in downcycles. The set-side shows the limit: Samsung's own MX (smartphone) division posted a KRW 0.7 trillion operating loss in Q2 2026 on elevated component costs (Samsung Newsroom, https://news.samsung.com/global/samsung-electronics-announces-second-quarter-2026-results).

來源：news.samsung.com

The FY2025 10-K shows prices being raised and sticking, and in the same breath shows what caps them. The results table puts gross margin at 36% of net sales in 2025 against 33% in 2024, and MD&A attributes the three-point gain to 'higher volume and the impact of actions taken by management to improve profitability, including raising prices, reducing costs and increasing productivity.' Display is the cleanest case: after resetting its core rate from 107 to 120 Japanese yen to the dollar, 'we implemented pricing actions in the second half of 2024', and 'The effects of the price increases on slightly higher volumes in 2025, compared to the prior period, substantially offset the impact of resetting the core rate.' The ceiling is disclosed in the same document: Optical Communications and Display are 'subject to pricing pressure', concentrated customers 'may possess substantial leverage in negotiating contractual obligations', and a risk factor warns that 'Increasing our prices to our customers may cause certain of our customers to push out, cancel or refrain from purchasing our products'. Price that holds on the back of rising volume, against customers that concentrated, is moderate rather than strong.

來源：sec.gov

Item 1A states that "certain U.S. private vaccine market practices, including regarding discounts, rebates and returns, may cause us to realize significantly lower revenues than list prices," and that "in some instances, our competitors have been able to offer more attractive terms than we can, and they may continue to do so in the future." On the flu candidate it says that in a well-developed market Moderna "may need to offer more favorable terms to gain market share (which we may be unable to do), which may negatively impact our profitability." The Commercial section adds that its markets are "characterized, particularly in the U.S. (our largest market), by a fragmented end customer base, unpredictability in orders and seasonality of deliveries."

來源：sec.gov

Upstream supplier of DRAM/HBM and NAND to the AI datacenter buildout (server memory at a record share of its Q2 2026 sales mix; HBM4E samples shipped to major customers) and a contract foundry, while simultaneously a downstream device maker (Galaxy) that consumes its own components (Samsung Newsroom, https://news.samsung.com/global/samsung-electronics-announces-second-quarter-2026-results).

Corning sits a layer beneath the AI build-out, supplying the glass and fiber rather than the compute. The FY2025 10-K describes 'optical fiber, cable and connectivity solutions for advanced communications networks, such as fiber to the home and data centers, enabling artificial intelligence', and says 'the rapid acceleration of artificial intelligence ("AI") is driving strong demand for fiber and connectivity products inside and between data centers', citing purpose-built parts such as the SMF-28e Contour fiber, 'a 40% smaller fiber', and the Contour Flow Cable 'which can fit double the fiber into the same cable diameter'. It also sells into chipmaking, through HPFS Fused Silica, ULE Ultra-Low Expansion Glass and the EXTREME ULE Glass introduced in 2024 to 'support chip manufacturers in meeting the rapidly growing demand for advanced and intelligent technologies'. The exposure is already in the numbers: Optical Communications net sales rose 35% to $6,274 million in 2025, which the filing attributes first to 'continued growth in our Enterprise business driven by strong demand for our Generative AI products'.

A vertically integrated mRNA developer-manufacturer that sits between upstream licensors and government or retail buyers: it in-licenses the Penn modified-mRNA patents non-exclusively through Cellscript and mRNA RiboTherapeutics at low-single-digit royalties and NIAID's prefusion coronavirus spike and prefusion RSV F patents, manufactures drug substance at the owned Norwood MTC campus and individualized therapy at Marlborough, runs Moderna-built plants in the UK, Canada and Australia against multi-year government purchase commitments, and relies on CMOs for critical raw material production and fill-finish.

• DRAM (incl. HBM) 領先 · 深 來源：trendforce.com
• Foundry (Samsung Foundry) 挑戰者 · 深 來源：telecomlead.com
• Galaxy smartphones 領先 · 中等 來源：androidauthority.com
• NAND flash 領先 · 中等 來源：trendforce.com

• Automotive ceramic substrates and particulate filters 未知 · 中等 來源：sec.gov
• Corning Gorilla Glass cover materials 未知 · 中等 來源：sec.gov
• Display glass substrates 領先 · 深 來源：sec.gov
• Hemlock hyper-pure polysilicon and solar products 未知 · 低 來源：sec.gov
• Life Sciences labware and consumables 未知 · 低 來源：sec.gov
• Optical fiber, cable and connectivity solutions 領先 · 中等 來源：sec.gov
• Semiconductor and precision optics 未知 · 中等 來源：sec.gov

• Intismeran autogene (mRNA-4157) 未知 · 中等 來源：sec.gov
• Spikevax 前三 · 中等 來源：sec.gov
• mNEXSPIKE 前三 · 中等 來源：sec.gov
• mRESVIA 挑戰者 · 中等 來源：sec.gov
• mRNA-1010 seasonal influenza vaccine 未知 · 中等 來源：sec.gov

編輯先驗，未經回測。

檢視它究竟如何投票 →

編輯先驗，未經回測。

檢視它究竟如何投票 →

編輯先驗，未經回測。

檢視它究竟如何投票 →